Janssen Pharmaceutical Inc.
Titusville
New Jersey
United States
615 articles about Janssen Pharmaceutical Inc.
-
Elmiron/Pentosan Users Who Have Developed Maculopathy and Other Eye Issues After Prolonged Use: James Scott Farrin is Ready to Fight For You
7/17/2020
The Law Offices of James Scott Farrin is taking cases for long-term Elmiron/pentosan users who subsequently developed maculopathy and other eye or vision issues. [17-July-2020] DURHAM, N.C. , July 17, 2020 /PRNewswire/ -- Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has come under fire for their ongoing failure to warn users of the harm their widely
-
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
7/17/2020
First data to read out from the Janssen and MeiraGTx collaboration Johnson & Johnson to review interim Phase 1/2 clinical trial findings in pre-recorded webcast Company anticipates progressing the program to Phase 3
-
TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
7/14/2020
In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis
-
In announcing the approval this morning, Janssen said IL-23 is a naturally occurring cytokine involved in normal inflammatory and immune responses associated with symptoms of psoriatic arthritis.
-
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
7/6/2020
Emergent BioSolutions Inc. announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology.
-
Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
-
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
6/26/2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA ® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.
-
Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
6/13/2020
Phase 3 ANDROMEDA study investigated the first and only subcutaneous anti-CD38 monoclonal antibody in treatment of rare multi-system disease with a high unmet medical need and for which there are currently no approved therapies Data selected as late-breaking abstract and featured in press briefing at European Hematology Association (EHA) Annual Congress [13-June-2020]
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
-
Janssen Highlights Innovative Oncology Portfolio and Pipeline of Oral, Biologic and Cell Therapies Through ASCO20 Virtual Scientific Program
5/29/2020
Presentations Distinguish Robust, Diverse Oncology Portfolio and Pipeline Across Hematologic Malignancies, Prostate Cancer and Solid Tumors
-
Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
5/18/2020
Teclistamab Data Featured as an Oral Presentation during ASCO Virtual Scientific Program
-
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
5/18/2020
Amivantamab-treated patients achieved durable remissions in CHRYSALIS study; data will be presented during ASCO Virtual Scientific Program [18-May-2020] RARITAN, N.J. , May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 1 CHRYSALIS study ( NCT02609776 ) evaluating amivantamab (JNJ-6372) in
-
/C O R R E C T I O N -- The Janssen Pharmaceutical Companies of Johnson & Johnson/
5/4/2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
-
Alveo Technologies Announces Research Collaboration with Janssen Pharmaceuticals, Inc. to Advance At-Home Testing Platform for Viral Infectious Diseases
4/30/2020
Alveo Technologies , a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™ platform of analyzers, nasal swabs and cartridges for the dete
-
Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
4/29/2020
Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity Catalent to hire 300 additional personnel to meet operational readiness and 24x7 manufacturing schedules
-
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
4/24/2020
Submissions demonstrate Janssen's commitment to developing new options for young patients
-
Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally
4/23/2020
First in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19